ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.7
(-1.32%)
TWD 18.7
(-1.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.35 Billion TWD | -7.12% |
| 2022 | 1.46 Billion TWD | 23.81% |
| 2021 | 1.18 Billion TWD | -10.42% |
| 2020 | 1.31 Billion TWD | -6.88% |
| 2019 | 1.41 Billion TWD | -30.12% |
| 2018 | 2.02 Billion TWD | -11.38% |
| 2017 | 2.28 Billion TWD | -10.61% |
| 2016 | 2.55 Billion TWD | 8.06% |
| 2015 | 2.36 Billion TWD | 18.73% |
| 2014 | 1.99 Billion TWD | 8.18% |
| 2013 | 1.84 Billion TWD | 51.21% |
| 2012 | 1.21 Billion TWD | 39.8% |
| 2011 | 870.9 Million TWD | 40.25% |
| 2010 | 620.97 Million TWD | -54.07% |
| 2009 | 1.35 Billion TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.44 Billion TWD | 6.83% |
| 2024 Q2 | 1.62 Billion TWD | 11.99% |
| 2023 Q1 | 1.51 Billion TWD | 3.57% |
| 2023 Q3 | 1.32 Billion TWD | -22.66% |
| 2023 Q4 | 1.35 Billion TWD | 2.45% |
| 2023 Q2 | 1.71 Billion TWD | 13.19% |
| 2023 FY | 1.35 Billion TWD | -7.12% |
| 2022 Q4 | 1.46 Billion TWD | 8.75% |
| 2022 Q2 | 1.65 Billion TWD | 27.04% |
| 2022 Q1 | 1.3 Billion TWD | 10.24% |
| 2022 FY | 1.46 Billion TWD | 23.81% |
| 2022 Q3 | 1.34 Billion TWD | -18.71% |
| 2021 Q2 | 1.69 Billion TWD | 23.88% |
| 2021 Q4 | 1.18 Billion TWD | 4.7% |
| 2021 Q1 | 1.36 Billion TWD | 3.75% |
| 2021 FY | 1.18 Billion TWD | -10.42% |
| 2021 Q3 | 1.12 Billion TWD | -33.43% |
| 2020 Q4 | 1.31 Billion TWD | -13.05% |
| 2020 Q2 | 1.72 Billion TWD | 14.12% |
| 2020 Q1 | 1.51 Billion TWD | 6.97% |
| 2020 FY | 1.31 Billion TWD | -6.88% |
| 2020 Q3 | 1.51 Billion TWD | -12.26% |
| 2019 Q3 | 1.41 Billion TWD | -55.58% |
| 2019 Q4 | 1.41 Billion TWD | 0.16% |
| 2019 Q2 | 3.17 Billion TWD | 9.24% |
| 2019 Q1 | 2.91 Billion TWD | 43.8% |
| 2019 FY | 1.41 Billion TWD | -30.12% |
| 2018 Q4 | 2.02 Billion TWD | -8.65% |
| 2018 FY | 2.02 Billion TWD | -11.38% |
| 2018 Q1 | 2.43 Billion TWD | 6.74% |
| 2018 Q2 | 2.72 Billion TWD | 11.78% |
| 2018 Q3 | 2.21 Billion TWD | -18.69% |
| 2017 Q1 | 2.49 Billion TWD | -2.36% |
| 2017 FY | 2.28 Billion TWD | -10.61% |
| 2017 Q4 | 2.28 Billion TWD | -9.3% |
| 2017 Q3 | 2.51 Billion TWD | -4.94% |
| 2017 Q2 | 2.64 Billion TWD | 6.19% |
| 2016 FY | 2.55 Billion TWD | 8.06% |
| 2016 Q3 | 2.41 Billion TWD | -6.71% |
| 2016 Q2 | 2.58 Billion TWD | 5.02% |
| 2016 Q1 | 2.46 Billion TWD | 4.2% |
| 2016 Q4 | 2.55 Billion TWD | 5.85% |
| 2015 Q1 | 2.09 Billion TWD | 5.17% |
| 2015 FY | 2.36 Billion TWD | 18.73% |
| 2015 Q4 | 2.36 Billion TWD | 3.08% |
| 2015 Q3 | 2.29 Billion TWD | -5.37% |
| 2015 Q2 | 2.42 Billion TWD | 15.74% |
| 2014 Q3 | 1.91 Billion TWD | -27.29% |
| 2014 Q4 | 1.99 Billion TWD | 3.94% |
| 2014 FY | 1.99 Billion TWD | 8.18% |
| 2014 Q2 | 2.63 Billion TWD | 18.61% |
| 2014 Q1 | 2.22 Billion TWD | 20.68% |
| 2013 Q3 | 1.77 Billion TWD | -31.66% |
| 2013 FY | 1.84 Billion TWD | 51.21% |
| 2013 Q1 | 1.57 Billion TWD | 29.42% |
| 2013 Q2 | 2.59 Billion TWD | 64.56% |
| 2013 Q4 | 1.84 Billion TWD | 3.88% |
| 2012 Q4 | 1.21 Billion TWD | 37.82% |
| 2012 FY | 1.21 Billion TWD | 39.8% |
| 2012 Q2 | 1.45 Billion TWD | 66.08% |
| 2012 Q1 | 877.48 Million TWD | 0.76% |
| 2012 Q3 | 883.4 Million TWD | -39.38% |
| 2011 Q3 | 677.7 Million TWD | 11.57% |
| 2011 Q4 | 870.9 Million TWD | 28.51% |
| 2011 Q2 | 607.44 Million TWD | 0.0% |
| 2011 FY | 870.9 Million TWD | 40.25% |
| 2010 FY | 620.97 Million TWD | -54.07% |
| 2010 Q4 | 620.97 Million TWD | 0.0% |
| 2009 FY | 1.35 Billion TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | 65.039% |
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | 55.523% |
| Maywufa Company Ltd. | 794.91 Million TWD | -70.73% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 91.332% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -2578.95% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | 62.275% |
| PhytoHealth Corporation | 79.84 Million TWD | -1599.653% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | 14.687% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | 74.988% |
| PharmaEssentia Corporation | 3.32 Billion TWD | 59.136% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 89.785% |